Co-treatment of imatinib-resistant disease with an ILK inhibitor and ponatinib results in increased survival, concomitant with increased fibronectin deposition and β3-integrin expression, suggesting that modulating these interactions in the BMM influence leukemia progression and clinical outcome in TKI-resistant CML in vivo [76]. The gene discussed is ILK; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.